IP Library Granted Patent US 7,632,925
Granted Patent B2
US 7,632,925 · App. 11/860,242 · Granted Dec 15, 2009

Antibodies that bind human 17-A1/EpCAM tumor antigen

Assignee: Micromet AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,925
App. No.
11/860,242
Granted
Dec 15, 2009
Kind
B2
Abstract

The present invention provides an anti-human antibody or fragment thereof that is low or not immunogenic in humans. In particular, the antibodies or fragments are directed to human tumor antigens, preferably to the human tumor antigen 17-1A, also known as EpCAM, EGP or GA 733-2. Also provided are pharmaceutical compositions comprising the aforementioned antibodies or fragments thereto.

Claims (10)

1. An antibody or antibody fragment being low or not immunogenic in humans and recognizing the human 17-1A antigen as expressed on the surface of tumor cells, the antibody or antibody fragment comprising a human VH chain and a human VL chain, wherein at least said VH chain comprises three CDRs being encoded by nucleotides 91 to 105, 148 to 198 and 292 to 351 of SEQ ID NO: 143, and said VL chain comprises three CDRs encoded by nucleotides 70 to 102, 148 to 168 and 265 to 294 of SEQ ID NO: 147.

2. The antibody or antibody fragment according to claim 1 , which is an antibody fragment.

3. An antibody or antibody fragment comprising a human VH chain and a human VL chain, said antibody or antibody fragment recognizing the human 17-1A antigen as expressed on the surface of tumor cells, wherein at least said VH chain comprises three CDRs being encoded by nucleotides 91 to 105, 148 to 198 and 292 to 351 of SEQ ID NO: 143, and said VL chain comprises three CDRs encoded by nucleotides 70 to 102, 148 to 168 and 265 to 294 of SEQ ID NO: 147.

4. The antibody or antibody fragment according to claim 3 , said antibody or antibody fragment being low or not immunogenic in humans.

5. The antibody or antibody fragment according claim 3 , recognizing an epitope of the extracellular domain of the 17-1A antigen.

6. The antibody or antibody fragment according to claim 1 , further comprising, fused to said human VH and VL chains, immunoglobulin constant regions of heavy (CH) and light chains (CL), respectively, or non-immunoglobulin chains.

7. The antibody or antibody fragment according to claim 6 , wherein said constant region chains are from human IgG1 or IgG3.

8. The antibody or antibody fragment according to claim 1 , further comprising a radioisotope, a chemotherapeutic agent or a toxin linked to said human VH and VL chains.

9. The antibody or antibody fragment according to claim 1 , dispersed in a pharmaceutically acceptable carrier.

10. The antibody or antibody fragment according to claim 3 , dispersed in a pharmaceutically acceptable carrier.

Assignments (1)
CHANGE OF NAME Recorded Jan 29, 2013
From: MICROMET AG
To: AMGEN RESEARCH (MUNICH) GMBH
Reel/Frame 029717/0892 →
Priority Claims (1)
EP 97106109 · Apr 14, 1997 · regional
Continuity (3)
Continuation 1032569400 · Dec 19, 2002
Division 0940310700
Related Publication 20090081191A1 · Mar 26, 2009